Judith C. W. Marsh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Judith C. W. Marsh has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
Ghulam J. Mufti
Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
10 shared publicationsVictoria Potter
Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
6 shared publications- Antonio Pagliuca
Department of Haematological Medicine, King’s College Hospital, London, UK
4 shared publications - Francesco Grimaldi
Department of Clinical Medicine and Surgery Hematology Division University of Naples Federico II Naples Italy
3 shared publications Antonio M. Risitano
Federico II University of Naples, Naples, Italy
2 shared publicationsAustin G. Kulasekararaj
Haematology, King's College Hospital, London, UK
2 shared publications
Latest Publications
- 21 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (3) , 310-322
An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial
Platelet transfusion refractoriness results in adverse outcomes and increased health care costs. Managing refractoriness resulting from HLA alloimmunization necessitates the use of HLA antigen–matched platelets but requires a large platelet donor pool and does not guarantee full matching. We report the first randomized, double-blind, noninferiority, crossover trial comparing HLA epitope–matched (HEM) platelets with HLA standard antigen–matched (HSM) platelet transfusions. Alloimmunized, platelet-refractory, thrombocytopenic patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia were eligible. HEM platelets were selected using HLAMatchMaker epitope (specifically eplet) matching. Patients received up to 8 prophylactic HEM and HSM transfusions provided in random order. The primary outcome was 1-hour posttransfusion platelet count increment (PCI). Forty-nine patients were randomized at 14 UK hospitals. For intention to treat, numbers of evaluable transfusions were 107 and 112 for HEM and HSM methods, respectively. Unadjusted mean PCIs for HEM and HSM methods were 23.9 (standard deviation [SD], 15) and 23.5 (SD, 14.1), respectively (adjusted mean difference, −0.1; 95% confidence interval [CI], −2.9 to 2.8). Because the lower limit of the 95% CI was not greater than the predefined noninferiority limit, the HEM approach was declared noninferior to the HSM approach. There were no differences in secondary outcomes of platelet counts, transfusion requirements, and bleeding events. Adequate 1-hour PCI was more frequently observed, with a mean number of 3.2 epitope mismatches, compared with 5.5 epitope mismatches for inadequate 1-hour increments. For every additional epitope mismatch, the likelihood of an adequate PCI decreased by 15%. Epitope-matched platelets should be considered to support HLA alloimmunized patients. This trial was registered at www.isrctn.com as #ISRCTN23996532.
- 21 January 2021
- Published by American Society of Hematology in Blood
- Vol. 137 (3) , 310-322
An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial
Platelet transfusion refractoriness results in adverse outcomes and increased health care costs. Managing refractoriness resulting from HLA alloimmunization necessitates the use of HLA antigen–matched platelets but requires a large platelet donor pool and does not guarantee full matching. We report the first randomized, double-blind, noninferiority, crossover trial comparing HLA epitope–matched (HEM) platelets with HLA standard antigen–matched (HSM) platelet transfusions. Alloimmunized, platelet-refractory, thrombocytopenic patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia were eligible. HEM platelets were selected using HLAMatchMaker epitope (specifically eplet) matching. Patients received up to 8 prophylactic HEM and HSM transfusions provided in random order. The primary outcome was 1-hour posttransfusion platelet count increment (PCI). Forty-nine patients were randomized at 14 UK hospitals. For intention to treat, numbers of evaluable transfusions were 107 and 112 for HEM and HSM methods, respectively. Unadjusted mean PCIs for HEM and HSM methods were 23.9 (standard deviation [SD], 15) and 23.5 (SD, 14.1), respectively (adjusted mean difference, −0.1; 95% confidence interval [CI], −2.9 to 2.8). Because the lower limit of the 95% CI was not greater than the predefined noninferiority limit, the HEM approach was declared noninferior to the HSM approach. There were no differences in secondary outcomes of platelet counts, transfusion requirements, and bleeding events. Adequate 1-hour PCI was more frequently observed, with a mean number of 3.2 epitope mismatches, compared with 5.5 epitope mismatches for inadequate 1-hour increments. For every additional epitope mismatch, the likelihood of an adequate PCI decreased by 15%. Epitope-matched platelets should be considered to support HLA alloimmunized patients. This trial was registered at www.isrctn.com as #ISRCTN23996532.
- Open Access
- 22 October 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (20) , 3070-3079
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
Key Points: GRFS is similar between older and younger patients using FCC conditioning but comorbidities impact on outcome of SAA HSCT. Immunomodulatory B lymphocytes potentially contribute to control of alloreactivity and low GVHD after FCC HSCT.
- 22 October 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (20) , 3070-3079
Open AccessSimilar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
Key Points: GRFS is similar between older and younger patients using FCC conditioning but comorbidities impact on outcome of SAA HSCT. Immunomodulatory B lymphocytes potentially contribute to control of alloreactivity and low GVHD after FCC HSCT.
- Open Access
- 1 September 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (9) , e277-e284
The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia
- 1 September 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (9) , e277-e284
Open AccessThe Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia
- 19 March 2019
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (11) , e494-e496
Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag
- 19 March 2019
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (11) , e494-e496
Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag
- Open Access
- 1 March 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (3) , 488-495
Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia
- 1 March 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (3) , 488-495
Open AccessAllogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia
- 1 August 2018
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 32 (4) , 595-607
Somatic Mutations in Aplastic Anemia
- 1 August 2018
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 32 (4) , 595-607
Somatic Mutations in Aplastic Anemia
- Open Access
- 1 February 2017
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 23 (2) , 293-299
Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells
- 1 February 2017
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 23 (2) , 293-299
Open AccessMixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells
- 18 March 2016
- Published by Springer Nature in International Journal of Hematology
- Vol. 104 (2) , 159-167
Clinical significance of acquired somatic mutations in aplastic anaemia
Aplastic anaemia (AA) is frequently associated with other disorders of clonal haemopoiesis such as paroxysmal nocturnal haemoglobinuria (PNH), myelodysplastic syndrome (MDS) and T-large granular lymphocytosis. Certain clones may escape the immune attack within the bone marrow environment and proliferate and attain a survival advantage over normal haemopoietic stem cells, such as trisomy 8, loss of heterozygosity of short arm of chromosome 6 and del13q clones. Recently acquired somatic mutations (SM), excluding PNH clones, have been reported in around 20–25 % of patients with AA, which predispose to a higher risk of later malignant transformation to MDS/acute myeloid leukaemia. Furthermore, certain SM, such as ASXL1 and DNMT3A are associated with poor survival following immunosuppressive therapy, whereas PIGA, BCOR/BCORL1 predict for good response and survival. Further detailed and serial analysis of the immune signature in AA is needed to understand the pathogenetic basis for the presence of clones with SM in a significant proportion of patients.
- 18 March 2016
- Published by Springer Nature in International Journal of Hematology
- Vol. 104 (2) , 159-167
Clinical significance of acquired somatic mutations in aplastic anaemia
Aplastic anaemia (AA) is frequently associated with other disorders of clonal haemopoiesis such as paroxysmal nocturnal haemoglobinuria (PNH), myelodysplastic syndrome (MDS) and T-large granular lymphocytosis. Certain clones may escape the immune attack within the bone marrow environment and proliferate and attain a survival advantage over normal haemopoietic stem cells, such as trisomy 8, loss of heterozygosity of short arm of chromosome 6 and del13q clones. Recently acquired somatic mutations (SM), excluding PNH clones, have been reported in around 20–25 % of patients with AA, which predispose to a higher risk of later malignant transformation to MDS/acute myeloid leukaemia. Furthermore, certain SM, such as ASXL1 and DNMT3A are associated with poor survival following immunosuppressive therapy, whereas PIGA, BCOR/BCORL1 predict for good response and survival. Further detailed and serial analysis of the immune signature in AA is needed to understand the pathogenetic basis for the presence of clones with SM in a significant proportion of patients.
- Open Access
- 1 November 2014
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 20 (11) , 1711-1716
Nonmyeloablative Peripheral Blood Haploidentical Stem Cell Transplantation for Refractory Severe Aplastic Anemia
- 1 November 2014
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 20 (11) , 1711-1716
Open AccessNonmyeloablative Peripheral Blood Haploidentical Stem Cell Transplantation for Refractory Severe Aplastic Anemia
- 30 April 2013
- Published by Springer Nature in International Journal of Hematology
- Vol. 97 (5) , 573-580
Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia
Alemtuzumab, a humanized anti-CD52, IgG1 monoclonal antibody, is used to reduce graft-versus- host disease (GVHD) and aid engraftment after allogeneic haemopoietic stem cell transplant (HSCT). Its associated low incidence of GVHD makes it an attractive alternative to anti-thymocyte globulin (ATG) in transplant conditioning regimen for severe aplastic anaemia (SAA). We have reviewed the use of alemtuzumab-based conditioning regimen for HSCT in SAA and show that it results in sustained haematological engraftment, a very low incidence of chronic GVHD without an increase in viral infections. Intriguingly, alemtuzumab appears to induce tolerance post-HSCT with the findings of stable mixed T cell chimerism with full donor myeloid chimerism and the absence of chronic GVHD, and which persist on withdrawal of post-graft immunosuppression. Finally, its low toxicity profile may permit future application of HSCT to older patients with SAA who fail to respond to immunosuppressive therapy.
- 30 April 2013
- Published by Springer Nature in International Journal of Hematology
- Vol. 97 (5) , 573-580
Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia
Alemtuzumab, a humanized anti-CD52, IgG1 monoclonal antibody, is used to reduce graft-versus- host disease (GVHD) and aid engraftment after allogeneic haemopoietic stem cell transplant (HSCT). Its associated low incidence of GVHD makes it an attractive alternative to anti-thymocyte globulin (ATG) in transplant conditioning regimen for severe aplastic anaemia (SAA). We have reviewed the use of alemtuzumab-based conditioning regimen for HSCT in SAA and show that it results in sustained haematological engraftment, a very low incidence of chronic GVHD without an increase in viral infections. Intriguingly, alemtuzumab appears to induce tolerance post-HSCT with the findings of stable mixed T cell chimerism with full donor myeloid chimerism and the absence of chronic GVHD, and which persist on withdrawal of post-graft immunosuppression. Finally, its low toxicity profile may permit future application of HSCT to older patients with SAA who fail to respond to immunosuppressive therapy.